Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study
Bruin-Weller, M.D.; Pink, A.E.; Patrizi, A.; Gimenez-Arnau, A.M.; Agner, T.; Roquet-Gravy, P.-P.; Ferrucci, S.M.; Arenberger, P.; Svensson, A.; Schuttelaar, M.L.A.; Nosbaum, A.; Jayawardena, S.; Rizova, E.; Ardeleanu, M.; Eckert, L.; Ozturk, Z.E.
(2021) Journal of Dermatological Treatment, volume 32, issue 2, pp. 164 - 173
(Article)
Abstract
Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics,
... read more
treatment patterns, and outcomes of these patients using descriptive statistics. Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator’s Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.
show less
Download/Full Text
Keywords: Atopic dermatitis, patient-reported outcomes, quality of life, systemic therapy, Dermatology
ISSN: 0954-6634
Publisher: Informa Healthcare
Note: Funding Information: Medical writing provided by Lola McRae, PhD, editorial assistance provided by Roshnnie Manoj, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
(Peer reviewed)